2023-508100-38-00招募中3 期
SAFIR ABC10 : Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Unicancer
- 入组人数
- 450
- 试验地点
- 52
- 主要终点
- Progression-free survival defined as the time from randomisation to the first documented progression of disease (PD) as assessed by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. Patients alive and free of progression at the cut-off date will be censored at the last assessment date.
研究概览
简要总结
To evaluate whether maintenance treatment with MTTs to “actionable” targets (ESCAT I-III) after 4 cycles of 1L-SoC is superior to continuation of 1L-SoC in terms of progression-free survival (PFS).
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Screening phase - Signed a written informed consent form prior to any trial specific procedures (Consent #1)
- •Randomised trial - Signed a written informed consent form prior to any trial specific procedures (Consent #2)
- •Randomised trial - Molecular profile showing the tumour harbours at least one targetable molecular alteration with a MTT in the study portfolio (as determined by the trial MTB)
- •Randomised trial - Disease control (stable or responsive) after 4 cycles of 1L-SoC, compared to a pretreatment disease evaluation, as assessed by the investigator
- •Randomised trial - ECOG performance status of 0 or 1
- •Randomised trial - Presence of at least one evaluable lesion according to RECIST v1.1, or complete response to 12 weeks 1L-SoC
- •Randomised trial - Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.5 × 10⁹/L, platelet count ≥100 × 10⁹/L, and haemoglobin ≥9 g/dL
- •Randomised trial - Adequate liver function: total bilirubin level ≤1.5 × the upper limit of normal (ULN) range unless the patient has documented Gilbert syndrome, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤2.5 × ULN (AST and ALT ≤5 ULN when documented tumour liver involvement)
- •Randomised trial - Adequate renal function: estimated creatinine clearance ≥45 mL/min according to the Cockcroft-Gault formula
- •Randomised trial - Adequate cardiac function: left ventricular ejection fraction ≥50% at baseline as determined by either echocardiogram or multigated acquisition scan (MUGA)
- •Randomised trial - Adequate biliary drainage, with no evidence of ongoing infection
- •Screening phase - Histologically-proven intrahepatic, perihilar or distal cholangiocarcinoma, or gallbladder carcinoma (ampullary carcinoma excluded)
- •Randomised trial - Men, and women of childbearing potential (WOCBP) must agree to use adequate contraception for the duration of trial participation and as required after completing study treatment. Men must also agree to not donate sperm and women must agree to not donate oocytes during the specified period.
- •Randomised trial - Women of childbearing potential must have a negative serum pregnancy test performed within 3 days before the date of randomisation
- •Randomised trial - Willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests, and other study procedures
- •Randomised trial - Affiliated to a social security system or in possession of equivalent private health insurance (according to local country health provision arrangements)
- •Screening phase - De novo or recurrent, locally advanced (non-resectable) or metastatic disease
- •Screening phase - Availability of a suitable archived sample of primary or metastatic tumour tissue (frozen, or FFPE) or able to undergo a biopsy to obtain a suitable malignant tissue sample
- •Screening phase - Aged ≥18 years
- •Screening phase - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Screening phase - Estimated life expectancy >3 months
- •Screening phase - Candidate for 1L-SoC therapy, or has initiated first cycle of 1L-SoC therapy
- •Screening phase - Affiliated to a social security system or in possession of equivalent private health insurance (according to local country health provision arrangements).
排除标准
- •Screening phase - Contraindication to 1L-SoC
- •Randomised trial - Concurrent malignancy (other than ABC), with the exception of adequately treated conebiopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 5 years or more and are deemed at negligible risk for recurrence, are eligible for the trial
- •Randomised trial - Known active hepatitis B virus or hepatitis C virus infection or human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome
- •Screening phase - Individuals deprived of liberty or placed under protective custody or guardianship
- •Randomised trial - Any condition which in the Investigator’s opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol
- •Randomised trial - Women who are pregnant or breast-feeding
- •Randomised trial - Participation in another therapeutic trial within the 30 days prior to entering the study. Participation in an observational trial would be acceptable
- •Randomised trial - Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons
- •Randomised trial - Individuals deprived of liberty or placed under protective custody or guardianship
- •For patients assigned to receive oral therapies - Inability or unwillingness to swallow pills
- •For patients assigned to receive oral therapies - History of malabsorption syndrome or other condition that would interfere with enteral absorption.
- •Screening phase - Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons
- •Screening phase - Patients who are candidates for locoregional therapy
- •Screening phase - Contraindication to tumour biopsy in the absence of suitable archived sample of tumour tissue
- •Screening phase - Prior anticancer therapy in the palliative setting. Adjuvant capecitabine allowed if completed ≥ 183 days prior to study entry
- •Screening phase - Received more than 1 cycle of treatment with 1L-SoC
- •Screening phase - Prior treatment with any of the MTT under investigation in the SAFIR-ABC10 study
- •Screening phase - Current malignancies (other than ABC), with the exception of adequately treated conebiopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 5 years or more and are deemed at negligible risk for recurrence, are eligible for the trial
- •Screening phase - Any condition which in the Investigator’s opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol
- •Screening phase_Known microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancer at study entry
- •Randomised trial - Disease progression occurring at any time prior randomisation, or toxicity that led to the discontinuation of the 1L-SoC before 4 full cycles have been delivered
- •Randomised trial - Toxicities from 1L-SoC not resolved to Grade ≤ 2 (according to version 5.0 the National Cancer Institute - Common terminology criteria for adverse events [NCI-CTCAE v5.0]) before randomisation, with the exception of alopecia
- •Randomised trial - Contraindication or known hypersensitivity to the MTT for the molecular alteration found in the patient, or any component in their formulation
- •Randomised trial - (MSI-H) or (dMMR) cancers
- •Randomised trial - Major surgery within 4 weeks of randomisation
- •Randomised trial - Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed
- •Randomised trial - Known leptomeningeal disease. If leptomeningeal disease has been reported radiographically on baseline magnetic responance imaging (MRI), but is not suspected clinically by the investigator, the subject must be free of neurological symptoms.
结局指标
主要结局
Progression-free survival defined as the time from randomisation to the first documented progression of disease (PD) as assessed by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. Patients alive and free of progression at the cut-off date will be censored at the last assessment date.
Progression-free survival defined as the time from randomisation to the first documented progression of disease (PD) as assessed by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. Patients alive and free of progression at the cut-off date will be censored at the last assessment date.
次要结局
- Overall Survival (OS), defined as the time from randomisation to death due to any cause. Patients alive at the cut-off date will be censored on the last date the patient was known to be alive or lost to follow-up or withdraw consent.
- Objective response rate, defined as the proportion of patients achieving CR or partial response (PR) as assessed by the investigator according to RECIST v1.1. Objective response rate will be presented as the best response achieved compared to the disease assessment performed at randomisation.
- Time to treatment failure, defined as the time from patient starting their allocated treatment to the date at which a patient first experiences a treatment failure event.
- Progression-free survival after next line of treatment (PFS2), defined as the time from randomisation to the date of second progression or death, whichever occurs first. Patients alive and free of second progression at the cut-off date will be censored at the last assessment date.
- Duration of response, defined as the time from first documented PR or CR (compared to baseline measurement taken at randomisation) until the date of PD, as assessed by the investigator according to RECIST v1.1, or death from any cause whichever occurs first. Patients who are alive and have not progressed at the time of the analysis will be censored at their last evaluable tumour assessment.
研究者
Director of regulatory Affairs and Pharmacovigilance
Scientific
Unicancer
研究点 (52)
Loading locations...
相似试验
已完成
4 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272
招募中
3 期
Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy2024-519404-27-00Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi247
招募中
2 期
A study to determine how safe MB-CART2019.1 is and how well it works in children and adolescents with B cell neoplasms2023-506348-17-00Miltenyi Biomedicine GmbH12
招募中
2 期
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic CancerNCT07283705M.D. Anderson Cancer Center60
招募中
2 期
A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best investigator’s choice (BIC) in resistance to PD-1/PD-L1 blockade due to antibiotics (ATB) uptake in patients with advanced non-small cell lung cancer (NSCLC) - IMMUNOLIFE22024-517018-14-00Institut Gustave Roussy162